Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
Authors
Keywords
-
Journal
Pharmaceutics
Volume 12, Issue 12, Pages 1180
Publisher
MDPI AG
Online
2020-12-04
DOI
10.3390/pharmaceutics12121180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
- (2020) Wendy Ankrom et al. CTS-Clinical and Translational Science
- Ubrogepant: First Approval
- (2020) Lesley J. Scott DRUGS
- Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
- (2020) Jessica Ailani et al. HEADACHE
- Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
- (2020) Yanbo Yang et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
- (2020) Xiuyuan Zhao et al. JOURNAL OF NEUROLOGY
- Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
- (2020) Bixi Gao et al. Frontiers in Pharmacology
- Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
- (2020) Max Tsai et al. Clinical Pharmacology in Drug Development
- Lasmiditan: Its Development and Potential Use
- (2020) Amanda E. Macone et al. Clinical Pharmacology in Drug Development
- Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
- (2020) Vincent Martin et al. ADVANCES IN THERAPY
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
- (2020) James M Martinez et al. CEPHALALGIA
- Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials
- (2020) Yanbo Yang et al. CNS DRUGS
- Eptinezumab: First Approval
- (2020) Sohita Dhillon DRUGS
- Rimegepant: First Approval
- (2020) Lesley J. Scott DRUGS
- Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
- (2020) Jill Fiedler‐Kelly et al. HEADACHE
- COVID‐19 is a Real Headache!
- (2020) Hayrunnisa Bolay et al. HEADACHE
- Headache medication and the COVID-19 pandemic
- (2020) Antoinette MaassenVanDenBrink et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
- (2020) Bixi Gao et al. Frontiers in Neurology
- Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes
- (2020) Young Hee Choi Pharmaceutics
- The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms
- (2020) Abimael González-Hernández et al. CNS & Neurological Disorders-Drug Targets
- Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two Phase 3 randomized clinical trials
- (2020) David B. Clemow et al. CURRENT MEDICAL RESEARCH AND OPINION
- Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
- (2020) David Moreno-Ajona et al. CURRENT OPINION IN NEUROLOGY
- Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
- (2020) Lesley J. Scott DRUGS
- Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
- (2020) Abhijeet Jakate et al. HEADACHE
- Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant
- (2020) Erin G. Doty et al. HEADACHE
- Lasmiditan mechanism of action – review of a selective 5-HT1F agonist
- (2020) David B. Clemow et al. JOURNAL OF HEADACHE AND PAIN
- Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
- (2020) Min Hou et al. JOURNAL OF HEADACHE AND PAIN
- Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
- (2020) Virginia L. Stauffer et al. JOURNAL OF HEADACHE AND PAIN
- Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review
- (2020) Alicia Potter DeFalco et al. ANNALS OF PHARMACOTHERAPY
- Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- (2020) Yanbo Yang et al. CNS DRUGS
- Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
- (2020) Gary Berman et al. HEADACHE
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
- (2020) Anna Vaisman-Mentesh et al. Frontiers in Immunology
- Pharmacokinetics and pharmacodynamics of new acute treatments for migraine
- (2019) Chiara Lupi et al. Expert Opinion on Drug Metabolism & Toxicology
- Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
- (2019) Hans-Christoph Diener et al. CEPHALALGIA
- Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
- (2019) Dustin D Ruff et al. CEPHALALGIA
- Gepants for the treatment of migraine
- (2019) Andrea Negro et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice
- (2019) James Francescangeli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Optimising migraine treatment: from drug-drug interactions to personalized medicine
- (2019) Leda Marina Pomes et al. JOURNAL OF HEADACHE AND PAIN
- New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
- (2019) Damiana Scuteri et al. Frontiers in Pharmacology
- Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
- (2019) John H Krege et al. CEPHALALGIA
- The treatment efficacy of galcanezumab for migraine: a meta-analysis of randomized controlled trials
- (2019) Junjie Fang et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
- (2019) Li Shen Loo et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Rimegepant oral disintegrating tablet for migraine
- (2019) Lars Edvinsson LANCET
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
- (2019) Richard B. Lipton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine
- (2019) J.B. Fiedler‐Kelly et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
- (2019) Peter J Goadsby et al. CEPHALALGIA
- Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
- (2019) William Kielbasa et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
- (2019) Jan Lewis Brandes et al. CEPHALALGIA
- Lasmiditan: First Approval
- (2019) Yvette N. Lamb DRUGS
- Monoclonal antibodies for the prevention of migraine
- (2019) Bianca Raffaelli et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Profiling lasmiditan as a treatment option for migraine
- (2019) Martina Curto et al. EXPERT OPINION ON PHARMACOTHERAPY
- Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies
- (2019) Tina M. Oakes et al. HEADACHE
- Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
- (2019) Richard B. Lipton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Migraine
- (2019) Rebecca C. Burch et al. NEUROLOGIC CLINICS
- Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
- (2019) Abhijeet Jakate et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Erenumab safety and efficacy in migraine
- (2019) Changyu Zhu et al. MEDICINE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
- (2018) Orit Cohen-Barak et al. CEPHALALGIA
- Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
- (2018) Cristina Tassorelli et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Targeted 5-HT1F Therapies for Migraine
- (2018) Marta Vila-Pueyo Neurotherapeutics
- The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
- (2018) Bianca Raffaelli et al. Neurotherapeutics
- Galcanezumab: First Global Approval
- (2018) Yvette N. Lamb DRUGS
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
- (2018) HEADACHE
- Lasmiditan is an effective acute treatment for migraine
- (2018) Bernice Kuca et al. NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design and engineering of deimmunized biotherapeutics
- (2016) Karl E Griswold et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Drug-Drug Interactions in Headache Medicine
- (2016) Hossein Ansari et al. HEADACHE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation